Trial Profile
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2015
Price :
$35
*
At a glance
- Drugs Reparixin (Primary)
- Indications Reperfusion injury
- Focus Therapeutic Use
- Sponsors Dompe Spa
- 20 Jun 2014 New trial record
- 26 Nov 2008
- 22 Sep 2006